Lenalidomide G.L. (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to degradation of transcription factors Ikaros and Aiolos. This results in immunomodulation, anti‑angiogenic activity, and direct anti‑myeloma effects through apoptosis and cell‑cycle arrest.

The prescribed dose of Lenalidomide G.L. is determined by the treating physician based on the specific indication, disease stage, renal function, and individual patient factors. Patients should follow the dosing instructions provided by their healthcare professional.

Lenalidomide is classified as pregnancy category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both male and female patients. Use during breastfeeding is not recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy, while maintaining comparable anti‑myeloma efficacy. Choice of therapy depends on individual patient characteristics and physician judgment.

Lenalidomide G.L. should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Lenalidomide G.L. is taken orally, usually once daily on a schedule prescribed by the clinician. The tablets should be swallowed whole with water and taken at the same time each day, unless otherwise directed by a healthcare provider.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, and significant hepatic injury. Patients should be monitored closely for signs of infection, clotting events, and liver dysfunction throughout therapy.

Lenalidomide G.L. is contraindicated in pregnant women, patients with known hypersensitivity to lenalidomide or its excipients, and individuals who cannot adhere to required contraception measures. Caution is also advised for patients with severe renal impairment or uncontrolled infections.